Una Health is pleased to announce a new strategic partnership with Credo Diagnostics, enabling UK distribution of the VitaSIRO solo™ – a cutting-edge platform designed for rapid, multiplex PCR testing at the point of care.

This compact, standalone system brings the power of real-time PCR directly to frontline healthcare environments, providing lab-quality results for up to 6 targets from a range of sample types including UTM/VTM, saliva, urine, blood, and faeces.

A wide test menu will be made available, with two assays currently offered for evaluation:

• SARS-CoV-2, Influenza A/B, and RSV multiplex panel – Get results for all 4 respiratory targets in just 40 minutes.*
• MT-RNR1 genetic assay – Rapidly identify neonates at risk of aminoglycoside-induced hearing loss, with results in just 20 minutes from a buccal swab.

Designed for ease of use and scalability, VitaSIRO solo™ features a simple workflow, intuitive touchscreen interface, and POCT1-A connectivity, making it ideal for a variety of clinical environments, including:

• Rapid respiratory PCR testing during winter surges and outbreaks
• Early MT-RNR1 screening for neonatal and high-risk patient safety
• Infection control in hospitals, clinics, care homes, and community settings

This partnership marks a significant step forward in Una Health’s mission to expand access to advanced molecular diagnostics at the point of care – empowering faster clinical decisions, improved outcomes, and greater operational efficiency.

👉 Be ready for winter surges and safeguard newborns with fast, reliable PCR testing at the point of care. Book your VitaSIRO solo™ demo today to explore respiratory panels and MT-RNR1 screening.

*Pending CTDA approval